Open Payments 2.0 – Big Changes Are Forecast

Key Messages  Tucked into the latest opioid law are changes to the Sunshine Act. Beginning in 2022, drug and device companies now must report transfers of value to advance practice nurses and physician assistants. CMS also awarded a contract to analyze Open Payments data over the next five years. All drug and device should review both their Sunshine Act systems AND their reported payments BEFORE CMS comes knocking at the…

Transparency’s Uncertain Future

I just returned from speaking at CBI’s 10th Annual Forum on Transparency and Aggregate Spend.  After 10 years and 3 CMS Open Payments reporting cycles, I’m struck by how uncertain the once bright future of the Sunshine Act is.  Overall, the industry remains mired in a transactional mud under increasingly gray skies. Too many companies still obsess about putting the right transaction (or transfer of value or (ToV)) into the right…

Arguing about whether the sun is shining

Within the life sciences industry, there has been a lot of talk about physicians disputing payments reported to the Centers for Medicare and Medicaid Services (CMS) under the Physician Payments Sunshine Act (a.k.a. Open Payments).  Well it seems that the data for the 2014 reporting year is now in. Recently Policy and Medicine, quoting CMS reported that “[r]egistered physicians and teaching hospitals reviewed nearly 30% of the total value of the reported…

Streebo Secures Partnership with Whitelaw Compliance Group, LLC.

Houston, Texas – August 4th, 2015 – Today Streebo, Inc. and Whitelaw Compliance Group, LLC. announce that they have joined forces to support Streebo’s exciting new offering, Open Payments Analytics, which brings the power of analytics applied to the CMS Open Payments to our clients. “Streebo’s Open Payments Analytics platform is comprehensive and robust, allowing life sciences companies to examine their data side-by-side with their peers using multiple filters and…